...
首页> 外文期刊>American journal of cardiovascular drugs: drugs, devices, and other interventions >The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines?
【24h】

The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines?

机译:降压药对新发糖尿病的影响:是时候修改指南了吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Recent large hypertension trials have shown great differences in incidence of new-onset diabetes mellitus among patients receiving different antihypertensive drug therapies. The incidence of diabetes is unchanged or increased by the use of thiazide diuretics and beta-adrenoceptor antagonists (beta-blockers) and unchanged or decreased by ACE inhibitors, calcium channel blockers (CCBs), and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers). Recent results from ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) showed superiority of the 'new' combination of CCBs and ACE inhibitors over the 'old' or 'conventional' combination of beta-blockers and diuretics. In this review, the results from some of the large hypertension trials are discussed, and the hypotheses on how different antihypertensive drug regimens can affect glucose homeostasis are considered. The question now is whether the results from these recent trials should affect the choice of antihypertensive treatment, particularly for special groups. However, the key goal is still to reduce BP, and this usually requires combinations of drugs.
机译:最近的大型高血压试验显示,接受不同的降压药物治疗的患者中,新发糖尿病的发生率差异很大。使用噻嗪类利尿剂和β-肾上腺素能受体拮抗剂(β-受体阻滞剂)可使糖尿病的发生率不变或增加,而ACEI,钙通道阻滞剂(CCBs)和血管紧张素II 1型受体拮抗剂(血管紧张素受体阻滞剂)可使糖尿病的发生率不变或降低。 )。 ASCOT(盎格鲁-斯堪的纳维亚心脏预后试验)的最新结果显示,CCB和ACE抑制剂的“新”组合优于β受体阻滞剂和利尿剂的“旧”或“常规”组合。在这篇综述中,讨论了一些大型高血压试验的结果,并考虑了有关不同的降压药物疗法如何影响葡萄糖稳态的假设。现在的问题是,这些最新试验的结果是否会影响降压治疗的选择,尤其是对于特殊人群。然而,关键目标仍然是降低血压,这通常需要药物的组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号